394735-19-4

Basic information

• Product Name: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate
• Synonyms: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate
• CAS NO: 394735-19-4
• Molecular Formula: C₁₂H₂₁NO₃
• Molecular Weight: 227.30004
• Mol File: 394735-19-4.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 329.012°C at 760 mmHg
• Flash Point: 152.781°C
• Appearance: /
• Density: 1.044g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(394735-19-4)
• EPA Substance Registry System: tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate(394735-19-4)

Safety Data

• Hazardous Substances Data: 394735-19-4(Hazardous Substances Data)

Usage

General Description

Tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbamate is a chemical compound that belongs to the group of carbamates. It is derived from tert-butyl carbamate and 1-cyclobutyl-3-oxopropan-2-yl. tert-butyl (1-cyclobutyl-3-oxopropan-2-yl)carbaMate is commonly used in organic synthesis and pharmaceutical research as a building block for the preparation of various compounds with potential biological activities. It has a wide range of applications in the field of medicinal chemistry, including as a precursor for the synthesis of new drug candidates and as a tool for the study of enzyme inhibition and mechanism of action. Additionally, it has been investigated for its potential use in the treatment of neurological disorders and cancer.

InChI:InChI=1/C12H21NO3/c1-12(2,3)16-11(15)13-10(8-14)7-9-5-4-6-9/h8-10H,4-7H2,1-3H3,(H,13,15)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 816429-99-9 SCH 503034D 
• 17247-58-4 (Bromomethyl)cyclobutane 
• 1025799-39-6 2-(benzhydrylidene-amino)-3-cyclobutyl-propionic acid ethyl ester 
• 816430-02-1 ethyl 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoate 
• 394735-17-2 ethyl 2-amino-3-cyclobutylpropanoate 
• 565456-75-9 2-(tert-butoxycarbonylamino)-3-cyclobutylpropanoic acid 
• 394735-18-3 tert-butyl 3-cyclobutyl-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate 

Downstream Products

• 394730-60-0 boceprevir 
• 394735-22-9 tert-butyl 4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-ylcarbamate 
• 1036931-36-8 3-amino-4-cyclobutyl-2-hydroxybutanamide hydrochloride 
• 394735-28-5 (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3-hydroxy-4-oxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicylo[3.1.0]-hexane-2-carboxamide 
• 394735-25-2 {(S)-2-[(1R,2S,5S)-2-(2-Carbamoyl-1-cyclobutylmethyl-2-hydroxy-ethylcarbamoyl)-6,6-dimethyl-3-aza-bicyclo[3.1.0]hex-3-yl]-1-cyclohexyl-2-oxo-ethyl}-carbamic acid tert-butyl ester 
• 1373318-77-4 C₇⁽¹³⁾CH₁₆N₂O₂*ClH 
• 394735-20-7 (2-cyano-1-cyclobutylmethyl-2-hydroxyethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

PROCESS FOR PREPARATION OF BOCEPREVIR AND INTERMEDIATES THEREOF

THE PRESENT INVENTION RELATES TO AN IMPROVED PROCESS FOR THE PREPARATION OF (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3-[2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL] AMINO]-3,3-DIMETHYL-1-OXOBUTYL]-6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2(S)-CARBOXAMIDE AND ITS INTERMEDIATES

PROCESS FOR THE SYNTHESIS OF 3-AMINO-3-CYCLOBUTYLMETHYL-2-HYDROXYPROPIONAMIDE OR SALTS THEREOF

A process for preparing 3-amino-3-cyclobutylmethyl-2-hydroxypropionamide of the Formula I: [Chemical formula should be inserted here as it appears in the paper abstract.] or a salt thereof involves providing a compound of the Formula VI described herein in a solution comprising predominately dimethylsulfoxide (DMSO) and converting this compound directly to the compound of the Formula VIII described herein without working up or isolating the intermediate compound of the Formula VII described herein.

Pharmaceutical formulations and methods of treatment using the same

Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.